Figure 4From: First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease modelTau vaccine improves sensorimotor functions of transgenic rats. Tau vaccine–treated transgenic rats showed decreased escape latency (A) and reduced hindlimb slips (B) compared to adjuvant-treated controls. Tau vaccine–treated transgenic rats had significantly lower NeuroScale scores than adjuvant controls, which reflects an improvement of sensorimotor functions (C), *P < 0.05.Back to article page